. Author manuscript; available in PMC: 2020 Jul 18.

Published in final edited form as: Cephalalgia. 2020 Mar 12;40(8):818–827. doi: 10.1177/0333102420911461

Table 2.

Treatment response for responders versus non-responders stratified by headache frequency and treatment group.

	Total		Low-frequency episodic migraine		High-frequency episodic migraine		Chronic migraine
	Responder	Non-responder	Responder	Non-responder	Responder	Non-responder	Responder	Non-responder

Dexamethasone	4 (30.8%)	9 (69.2%)	1 (50.0%)	1 (50.0%)	1 (33.3%)	2 (66.7%)	2 (25.0%)	6 (75.0%)
Ketorolac	1 (11.1%)	8 (88.9%)	0 (0.0%)	2(100%)	1 (25.0%)	3 (75.0%)	0 (0.0%)	3 (100%)
Naratriptan	1 (11.1%)	8 (88.9%)	1 (33.3%)	2 (66.7%)	0 (0.0%)	3 (100%)	0 (0.0%)	3 (100%)
Nerve block	7 (24.1%)	22 (75.9%)	3 (25.0%)	9 (75.0%)	2 (40.0%)	3 (60.0%)	2(16.7%)	10(83.3%)
Total	13 (21.7%)	47 (78.3%)	5 (26.3%)	14(73.7%)	4 (26.7%)	11 (73.3%)	4(15.4%)	22 (84.6%)